Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Estimating the probability of overdiagnosis in PLCO trial

Principal Investigator
Name
Jian-Lun Xu
Degrees
Ph.D
Institution
NCI
Position Title
Mathematical Statistician
Email
About this CDAS Project
Study
PLCO (Learn more about this study)
Project ID
PLCO-600
Initial CDAS Request Approval
Mar 25, 2020
Title
Estimating the probability of overdiagnosis in PLCO trial
Summary
Screening procedures are widely recommended by various professional and advocacy groups and utilized for early detection of diseases such as cancer with the goal of detecting disease early, before it becomes symptomatic. The hope is that treatment may be easier and more effective, increasing patient life span when the disease is detected at an earlier stage. While the potential value of early detection is clear, it is offset in part by the occurrence of false (positive or negative) results and overdiagnosis. Compared to false results, overdiagnosis has received little attention because it is a challenging concept to understand and communicate and cannot be directly measured. In this project, we develop a model to estimate the probability of overdiagnosis in a repeated screening program. The asymptotic normality of the estimate is proved. In addition, we apply the model and method to the data from PLCO trial.
Aims

• Develop a model to estimate the probability of overdiagnosis.
• Study the asymptotic property of the estimate.
• Apply the model and method to each screening modality in the PLCO trial.

I need the following data from each of screening modalities:
1. Control group:
nc = number of cancers diagnosed clinically,
Nc = sample size of control group.
2. Intervention group:
nrc = number of cancers diagnosed clinically in the refusal group,
Nrc = number of individuals in the refusal group,
nsc = number of cancers detected by a screening modality,
nic = number of interval cancers from a screening modality,
Ni = sample size of intervention group.
pn = post screen cases in the intervention arm.

Collaborators

Philip C. Prorok
Division of Cancer Prevention
National Cancer Institute